Insight Molecular Diagnostics Inc. — Director's Dealing 2022

Dec 28, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2022-12-23

Reporting Person: Gutfreund John Peter (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-23	Common Stock, no par value	P	75000	$0.3297	Acquired	75000	Indirect

Footnotes

F1: The price of $0.3297 per share represents a weighted average of prices ranging from $0.31 to $0.33 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: The shares of common stock are held by Newtown Road 130 Holdings LLC. The Reporting Person is the Managing Member of Newtown Road 130 Holdings LLC and in such capacity has the right to vote and dispose of the securities held by such entity.